BMC Infectious Diseases (Jan 2018)

Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil

  • Guilherme Amaral Calvet,
  • Edna Oliveira Kara,
  • Silvana Pereira Giozza,
  • Camila Helena Aguiar Bôtto-Menezes,
  • Philippe Gaillard,
  • Rafael Freitas de Oliveira Franca,
  • Marcus Vinicius Guimarães de Lacerda,
  • Marcia da Costa Castilho,
  • Patrícia Brasil,
  • Patrícia Carvalho de Sequeira,
  • Maeve Brito de Mello,
  • Ximena Pamela Diaz Bermudez,
  • Kayvon Modjarrad,
  • Robyn Meurant,
  • Sihem Landoulsi,
  • Adele Schwartz Benzaken,
  • Ana Maria Bispo de Filippis,
  • Nathalie Jeanne Nicole Broutet,
  • for the ZIKABRA Study Team

DOI
https://doi.org/10.1186/s12879-018-2965-4
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Background Zika virus (ZIKV) has been identified in several body fluids of infected individuals. In most cases, it remained detected in blood from few days to 1 week after the onset of symptoms, and can persist longer in urine and in semen. ZIKV infection can have dramatic consequences such as microcephaly and Guillain-Barré syndrome. ZIKV sexual transmission has been documented. A better understanding of ZIKV presence and persistence across biologic compartments is needed to devise rational measures to prevent its transmission. Methods This observational cohort study will recruit non-pregnant participants aged 18 years and above with confirmed ZIKV infection [positive reverse transcriptase-polymerase chain reaction (RT-PCR) test in blood and/or urine]: symptomatic men and women in ZIKV infection acute phase, and their symptomatic or asymptomatic household/sexual infected contacts. Specimens of blood, urine, semen, vaginal secretion/menstrual blood, rectal swab, oral fluids, tears, sweat, urine and breast milk (if applicable) will be collected at pre-established intervals and tested for ZIKV RNA presence by RT-PCR, other co-infection (dengue, Chikungunya, HIV, hepatitis B and C, syphilis), antibody response (including immunoglobulins M and G), plaque reduction neutralization test (if simultaneously positive for ZIKV and dengue), and ZIKV culture and RNA sequencing. Data on socio-demographic characteristics and comorbidities will be collected in parallel. Participants will be followed up for 12 months. Discussion This prolonged longitudinal follow-up of ZIKV infected persons with regular biologic testing and data collection will offer a unique opportunity to investigate the presence and persistence of ZIKV in various biologic compartments, their clinical and immunological correlates as well as the possibility of ZIKV reactivation/reinfection over time. This valuable information will substantially contribute to the body of knowledge on ZIKV infection and serve as a base for the development of more effective recommendation on the prevention of ZIKV transmission. Trial registration NCT03106714 . Registration Date: April, 7, 2017

Keywords